RCP Therapeutics, a biopharmaceuticals company specialising in converging nanotechnology and regenerative medical markets, has exclusively licensed technologies from Telemolecular.
RCP aggregates intellectual property, performs early stage proof of concept in pre-clinical and forms partnerships with pharmaceutical companies in later stage clinical studies.
RCP has identified a series of product candidates and has pilot launched its lead product candidate, Bimene, a cosmetic topical product, utilising its nano particle delivery platform bought with licences from universities and US-based research institutions.
The company's technology treats injuries resulting from stroke ischemia and reperfusion injury; clinical trials will begin in 2009.
The company has also identified and performed early trials using a p53 nano particle to treat the effects of restenosis following angioplasty.
Telomolecular will expand its Sacramento research laboratory, where it will commercialise RCP Therapeutics' cosmetic products.
